Banner - NPPA Connect

All Videos

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gaps in atopic dermatitis management for various patient subgroups.

Michael Lewitt, MD, discusses a case involving a 7-year-old girl with plaque psoriasis (PsO) affecting body surface area (BSA) and the face, emphasizing the limited pediatric treatment options and the psychological and social impact on the child; the family initially opted for topical treatments like roflumilast, but preferred a more proactive approach, transitioning to apremilast while addressing concerns about gastrointestinal adverse events and the patient’s aversion to needles.

Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.

Ted Lain, MD, MBA, FAAD, is featured in this series.

Ted Lain, MD, MBA, FAAD, discusses how selecting the optimal photodynamic therapy approach involves considering factors such as the specific disease characteristics, patient conditions, available photosensitizers, light sources, and potential combinations with other treatments to maximize efficacy and minimize adverse effects.

Ted Lain, MD, MBA, FAAD, is featured in this series.

Ted Lain, MD, MBA, FAAD, discusses how a combination approach in photodynamic therapy integrates multiple treatment modalities or agents to enhance therapeutic efficacy and overcome limitations of standalone photodynamic treatments for various cancers and other diseases.